Cargando…
Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106106/ https://www.ncbi.nlm.nih.gov/pubmed/36747351 http://dx.doi.org/10.1097/LVT.0000000000000087 |
| _version_ | 1785026352328474624 |
|---|---|
| author | Di Marco, Lorenza Pivetti, Alessandra Foschi, Francesco Giuseppe D’Amico, Roberto Schepis, Filippo Caporali, Cristian Casari, Federico Lasagni, Simone Critelli, Rosina Maria Milosa, Fabiola Romanzi, Adriana Marcelli, Gemma De Maria, Nicola Romagnoli, Dante Catellani, Barbara Scianò, Filippo Magistri, Paolo Colecchia, Antonio Sighinolfi, Pamela Di Benedetto, Fabrizio Martinez-Chantar, Maria-Luz Villa, Erica |
| author_facet | Di Marco, Lorenza Pivetti, Alessandra Foschi, Francesco Giuseppe D’Amico, Roberto Schepis, Filippo Caporali, Cristian Casari, Federico Lasagni, Simone Critelli, Rosina Maria Milosa, Fabiola Romanzi, Adriana Marcelli, Gemma De Maria, Nicola Romagnoli, Dante Catellani, Barbara Scianò, Filippo Magistri, Paolo Colecchia, Antonio Sighinolfi, Pamela Di Benedetto, Fabrizio Martinez-Chantar, Maria-Luz Villa, Erica |
| author_sort | Di Marco, Lorenza |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10106106 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101061062023-04-17 Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma Di Marco, Lorenza Pivetti, Alessandra Foschi, Francesco Giuseppe D’Amico, Roberto Schepis, Filippo Caporali, Cristian Casari, Federico Lasagni, Simone Critelli, Rosina Maria Milosa, Fabiola Romanzi, Adriana Marcelli, Gemma De Maria, Nicola Romagnoli, Dante Catellani, Barbara Scianò, Filippo Magistri, Paolo Colecchia, Antonio Sighinolfi, Pamela Di Benedetto, Fabrizio Martinez-Chantar, Maria-Luz Villa, Erica Liver Transpl Brief Reports Lippincott Williams & Wilkins 2023-05 2023-02-08 /pmc/articles/PMC10106106/ /pubmed/36747351 http://dx.doi.org/10.1097/LVT.0000000000000087 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Brief Reports Di Marco, Lorenza Pivetti, Alessandra Foschi, Francesco Giuseppe D’Amico, Roberto Schepis, Filippo Caporali, Cristian Casari, Federico Lasagni, Simone Critelli, Rosina Maria Milosa, Fabiola Romanzi, Adriana Marcelli, Gemma De Maria, Nicola Romagnoli, Dante Catellani, Barbara Scianò, Filippo Magistri, Paolo Colecchia, Antonio Sighinolfi, Pamela Di Benedetto, Fabrizio Martinez-Chantar, Maria-Luz Villa, Erica Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title | Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title_full | Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title_fullStr | Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title_full_unstemmed | Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title_short | Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| title_sort | feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma |
| topic | Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106106/ https://www.ncbi.nlm.nih.gov/pubmed/36747351 http://dx.doi.org/10.1097/LVT.0000000000000087 |
| work_keys_str_mv | AT dimarcolorenza feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT pivettialessandra feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT foschifrancescogiuseppe feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT damicoroberto feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT schepisfilippo feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT caporalicristian feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT casarifederico feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT lasagnisimone feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT critellirosinamaria feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT milosafabiola feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT romanziadriana feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT marcelligemma feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT demarianicola feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT romagnolidante feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT catellanibarbara feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT scianofilippo feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT magistripaolo feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT colecchiaantonio feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT sighinolfipamela feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT dibenedettofabrizio feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT martinezchantarmarialuz feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma AT villaerica feasibilitysafetyandoutcomeofsecondlinenivolumabbevacizumabinlivertransplantpatientswithrecurrenthepatocellularcarcinoma |